KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Long-Term Investments: 2014-2019

Historic Long-Term Investments for Travere Therapeutics (TVTX) over the last 1 years, with Jun 2019 value amounting to $15.0 million.

  • Travere Therapeutics' Long-Term Investments changed negligibly% to $15.0 million in Q2 2019 from the same period last year, while for Jun 2019 it was $15.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $15.0 million for FY2018, which is N/A change from last year.
  • Latest data reveals that Travere Therapeutics reported Long-Term Investments of $15.0 million as of Q2 2019, which was down 0.00% from $15.0 million recorded in Q1 2019.
  • Over the past 5 years, Travere Therapeutics' Long-Term Investments peaked at $15.0 million during Q1 2018, and registered a low of $15.0 million during Q1 2018.
  • Over the past 2 years, Travere Therapeutics' median Long-Term Investments value was $15.0 million (recorded in 2019), while the average stood at $15.0 million.